Development and License Agreements - Additional Information (Detail) - USD ($)	1 Months Ended	3 Months Ended		6 Months Ended
	Sep. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Licenses Agreements [Line Items]
Payments made relating to the manufacturing of the products		$ 10,400,000	$ 6,300,000	$ 22,200,000	$ 14,400,000
BARDA Agreement
Licenses Agreements [Line Items]
Additional committed fund receivable		9,600,000		9,600,000
Committed fund receivable		126,500,000		126,500,000
Committed fund receivable		223,500,000		223,500,000
Accounts receivable of billed and unbilled amounts		4,800,000		4,800,000		$ 4,600,000
BARDA Agreement | Cerus Corporation
Licenses Agreements [Line Items]
Co-investment by the company				5,000,000.0
Additional co-investment by the company				9,600,000
Co-investment incurred by the company				2,800,000
FDA Agreement
Licenses Agreements [Line Items]
Accounts receivable of billed and unbilled amounts		$ 200,000		$ 200,000
Contract agreement term	5 years
Total potential contract value	$ 11,100,000
FDA Agreement | Maximum
Licenses Agreements [Line Items]
Accounts receivable of billed and unbilled amounts						$ 100,000